Regulation of Protein Synthesis and Apoptosis in Lymphocytes of Parkinson Patients: The Effect of Dopaminergic Treatment.


Journal

Neuro-degenerative diseases
ISSN: 1660-2862
Titre abrégé: Neurodegener Dis
Pays: Switzerland
ID NLM: 101189034

Informations de publication

Date de publication:
2019
Historique:
received: 05 12 2019
accepted: 31 12 2019
pubmed: 9 3 2020
medline: 18 9 2020
entrez: 9 3 2020
Statut: ppublish

Résumé

Parkinson disease (PD) is a neurodegenerative disorder characterized by progressive degeneration of the dopaminergic neurons in the substantia nigra, presumably due to increased apoptosis. In previous studies, we showed altered expression of proteins involved in mammalian target of rapamycin (mTOR) antiapoptotic and double-stranded RNA-dependent protein kinase (PKR) apoptotic pathways of translational control in experimental cellular and animal models of PD. In this work, our results showed clear modifications in the expression of kinases involved in mTOR and PKR apoptosis pathways, in lymphocytes of PD patients treated or not with anti-PD treatment (levodopa), which confirmed the role played by apoptosis in the pathogenesis of this disease and the positive effect of treatment with medication on this parameter. Others proteins involved in apo-ptosis were also evaluated in lymphocytes of patients as the expression of the peripheral benzodiazepine receptor and caspase-3. Translational control is altered in PD and hence its evaluation in peripheral blood mononuclear cells may serve as an early marker of apoptosis and indicate the efficacy of the dopaminergic treatment.

Sections du résumé

BACKGROUND
Parkinson disease (PD) is a neurodegenerative disorder characterized by progressive degeneration of the dopaminergic neurons in the substantia nigra, presumably due to increased apoptosis. In previous studies, we showed altered expression of proteins involved in mammalian target of rapamycin (mTOR) antiapoptotic and double-stranded RNA-dependent protein kinase (PKR) apoptotic pathways of translational control in experimental cellular and animal models of PD.
RESULTS
In this work, our results showed clear modifications in the expression of kinases involved in mTOR and PKR apoptosis pathways, in lymphocytes of PD patients treated or not with anti-PD treatment (levodopa), which confirmed the role played by apoptosis in the pathogenesis of this disease and the positive effect of treatment with medication on this parameter. Others proteins involved in apo-ptosis were also evaluated in lymphocytes of patients as the expression of the peripheral benzodiazepine receptor and caspase-3.
CONCLUSION
Translational control is altered in PD and hence its evaluation in peripheral blood mononuclear cells may serve as an early marker of apoptosis and indicate the efficacy of the dopaminergic treatment.

Identifiants

pubmed: 32146463
pii: 000505750
doi: 10.1159/000505750
doi:

Substances chimiques

Antiparkinson Agents 0
Dopamine Agents 0
Levodopa 46627O600J
MTOR protein, human EC 2.7.1.1
EIF2AK2 protein, human EC 2.7.11.1
TOR Serine-Threonine Kinases EC 2.7.11.1
eIF-2 Kinase EC 2.7.11.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

178-183

Informations de copyright

© 2020 S. Karger AG, Basel.

Auteurs

Stéphanie Pain (S)

INSERM U1084, Laboratoire de Neurosciences Expérimentales et Cliniques, LNEC, Université de Poitiers, Poitiers, France, stephanie.pain@univ-poitiers.fr.
Faculté de Médecine-Pharmacie, Université de Poitiers, Poitiers, France, stephanie.pain@univ-poitiers.fr.

Julie Deguil (J)

Faculté de Médecine-Pharmacie, Université de Poitiers, Poitiers, France.

Jeremie Belin (J)

Centre Expert Parkinson, Service de Neurologie, CHU de Tours, Tours, France.

Pauline Barraud (P)

Faculté de Médecine-Pharmacie, Université de Poitiers, Poitiers, France.

Stéphanie Ragot (S)

Faculté de Médecine-Pharmacie, Université de Poitiers, Poitiers, France.
INSERM, CIC 1402, Poitiers, France.

Jean-Luc Houeto (JL)

Faculté de Médecine-Pharmacie, Université de Poitiers, Poitiers, France.
Service de Neurologie, CHU Poitiers, Poitiers, France.
INSERM, CIC 1402, Poitiers, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH